Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: results from the phase Ib PORTIA study

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Ulrich Jaeger,1 Nina Worel,2 Joseph P. McGuirk,3 Peter A. Riedell,4 Isabelle Fleury,5 Yan, Du,6 Xia Han,7 David Pearson,8 Santiago Redondo,9 Edmund K. Waller10

Journal title: Blood Advances

Journal publisher: Elsevier Inc.

Published year: 2022

DOI identifier: 10.1182/bloodadvances.2022007779

ISSN: 2473-9537